Welcome to our dedicated page for Merck & Co. SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Merck & Co.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Merck & Co.'s regulatory disclosures and financial reporting.
Merck & Co., Inc. executive David R. Maraldo, EVP & President Merck Manufacturing Division, reported exercising stock options for a total of 18,706 shares of common stock on August 5, 2026, at exercise prices of $73.73, $87.10, and $84.71 per share. He then sold the resulting 18,706 shares in open-market transactions at a weighted average price of $128.7179 per share, with sale prices ranging from $128.64 to $128.85 per share.
Merck & Co., Inc. executive David Michael Williams, EVP and Chief Information & Digital Officer, exercised stock options covering 52,847 shares of common stock on August 5, 2026 at strike prices of $77.6200, $75.3600 and $73.7300 per share. He then sold all 52,847 shares at a weighted average price of $128.7707, with individual sale prices ranging from $128.7050 to $128.9700.
Merck & Co., Inc. executive Guindo Chirfi, EVP, Access, Policy & Comms, reported selling 15,000 shares of common stock on August 6, 2026 at $131.00 per share in an open‑market or private transaction. After the sale, he directly owned 46,613 shares of Merck common stock.
Merck & Co., Inc. reported sales of $16,607 million for the quarter and $32,893 million for the first half of 2026, modestly above 2025 levels. Very large research and development charges, however, turned profitability negative.
First-half R&D expenses rose to $22,333 million, including a $9.0 billion charge for the Cidara Therapeutics asset acquisition and $5.7 billion for Terns Pharmaceuticals. Merck recorded a first-half net loss attributable to shareholders of $5,575 million, versus net income of $9,506 million a year earlier, and diluted EPS of $(2.26) versus $3.77.
Operating cash flow strengthened to $9,288 million, but heavy investing outflows for Cidara, Terns and other transactions drove cash and cash equivalents down to $6,849 million at June 30, 2026, from $14,565 million at year-end, while long-term debt increased to $51,081 million.
Merck continued to expand its pipeline through acquisitions and collaborations, including the purchase of TARGAN for approximately $650 million, an FDA approval and milestone payments related to Welireg/Keytruda, and ongoing alliances with AstraZeneca, Eisai, Bayer, Ridgeback, Daiichi Sankyo, Moderna and BMS. Two multiyear restructuring programs added $800 million of pretax charges in the first half.
Merck & Co., Inc., as an institutional investment manager, filed a Form 13F holdings report covering its reportable equity investment positions. The report lists 1 other included manager, Merck Sharp & Dohme LLC, and an information table totaling 13 reportable entries with an aggregate reported value of $526,407,169, rounded to the nearest dollar. The report is signed by Corporate Secretary Kelly Grez, who certifies the accuracy and completeness of the information submitted.
Issuer MRK has a holder planning a Rule 144 sale of common stock. The notice covers 15,000 shares, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, with an aggregate value of $1,965,000.00 as of the notice. These shares were acquired as restricted stock vesting under a registered plan on 01/27/2025.
MRK has filed a notice of proposed sale of common stock. The filing references 6,050 common shares associated with a planned transaction on or after August 6, 2026 on the NYSE, with an associated value of $788,772.63.
The shares relate to prior acquisitions through restricted stock vesting under a registered plan, including 3,298 shares vested on February 23, 2015 and 2,752 shares vested on November 2, 2014.
Merck & Co., Inc. reported second-quarter 2026 sales of $16,607 million, up 5% from $15,806 million, with Pharmaceutical sales of $14,760 million and Animal Health sales of $1,775 million, both up 5% and 8%, respectively. Growth was led by oncology and cardiometabolic products, including KEYTRUDA/KEYTRUDA QLEX at $8,366 million and WINREVAIR at $588 million, up 75%.
The company recorded a GAAP net loss of $1,335 million (EPS $(0.54)) and a non-GAAP net loss of $330 million (EPS $(0.13)), versus GAAP EPS of $1.76 and non-GAAP EPS of $2.13 a year earlier. Results were driven by a $5.7 billion R&D charge for the acquisition of Terns Pharmaceuticals, equal to $2.31 per share, which also pushed non-GAAP R&D to $9.7 billion.
Merck highlighted major regulatory milestones, including FDA approval of LIPFENDRA, multiple new KEYTRUDA-based regimens, and additional vaccine indications. For full-year 2026, it raised sales guidance to $66.3–$67.3 billion but cut non-GAAP EPS guidance to $2.66–$2.76 from $5.04–$5.16, reflecting one-time acquisition charges of $9.0 billion for Cidara and $5.7 billion for Terns.